PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Authors
Keywords
Meta-analysis, Prognosis, Surgical resection, Publication ethics, Gastric cancer, T cells, China, Metastasis
Journal
PLoS One
Volume 12, Issue 8, Pages e0182692
Publisher
Public Library of Science (PLoS)
Online
2017-08-11
DOI
10.1371/journal.pone.0182692
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
- (2016) Changqing Ma et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Biomarkers of EBV-positive Gastric Cancers: Loss of PTEN Expression is Associated with Poor Prognosis and Nodal Metastasis
- (2016) Hyo Jeong Kang et al. ANNALS OF SURGICAL ONCOLOGY
- PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer
- (2016) Zhongwu Li et al. HUMAN PATHOLOGY
- Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer
- (2016) Congqi Dai et al. Molecular Oncology
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
- (2016) Sarah Derks et al. Oncotarget
- The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
- (2016) Minghui Zhang et al. Scientific Reports
- Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
- (2016) Xiaojun Liu et al. Therapeutic Advances in Gastroenterology
- Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
- (2015) Shohei Eto et al. Gastric Cancer
- Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer
- (2015) Feng Xu et al. MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
- (2015) Yi Qing et al. Drug Design Development and Therapy
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer
- (2014) Jingying Hou et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer
- (2014) Jin Won Kim et al. Gastric Cancer
- Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
- (2014) Yiting Geng et al. International Journal of Clinical Oncology
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Regulatory T Cells and Immune Tolerance
- (2008) Shimon Sakaguchi et al. CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started